Managing diabetic retinopathy

BMJ (Online)

Volumn 341, Issue 7779, 2010, Pages 930-935

  Ockrim, Zoe ^a   Yorston, David ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b Tennent Institute of Ophthalmology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANDESARTAN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; PEGAPTANIB; PIOGLITAZONE; RANIBIZUMAB; ROSIGLITAZONE; RUBOXISTAURIN; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

BLINDNESS; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC MACULOPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG COST; DRUG MECHANISM; EARLY DIAGNOSIS; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PERIPHERAL EDEMA; PHOTOGRAPHY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA DETACHMENT; RETINA MACULOPATHY; REVIEW; VITRECTOMY; VITREOUS HEMORRHAGE;

BLOOD GLUCOSE; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPERTENSION; LASER COAGULATION; MACULAR EDEMA; PHYSICAL EXAMINATION; RISK FACTORS; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 78049458726     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c5400     Document Type: Review

References (42)

1. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye 2008;22:905-11. [CrossRef] [Medline] [Web of Science]
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. [Abstract/FREE Full text]
3. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68. [Abstract]
4. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90:450-9. [Medline] [Web of Science]
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. [CrossRef] [Medline] [Web of Science]
6. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9. [Abstract/FREE Full text]
7. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307-13. [Abstract/FREE Full text]
8. Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt CJ. The retinal blood flow in diabetes. Diabetologia 1975;11:27-33. [CrossRef] [Medline] [Web of Science]
9. Addison DJ, Garner A, Ashton N. Degeneration of intramural pericytes in diabetic retinopathy. BMJ 1970;1:264-6. [Abstract/FREE Full text]
10. Zander E, Herfurth S, Bohl B, Heinke P, Herrmann U, Kohnert KD, et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol 2000;84:871-6. [Abstract/FREE Full text]
11. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806. [Abstract/FREE Full text]
12. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy J Med Screen 2008;216:1-4.
13. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy-a systematic review. Diabet Med 2000;17:495-506. [CrossRef] [Medline] [Web of Science]
14. Home P. Safety of very tight blood glucose control in type 2 diabetes. BMJ 2008;336:458-9. [Abstract/FREE Full text]
15. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). CG 66. 2008. www.nice.org.uk/CG066.
16. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61. [Medline] [Web of Science]
17. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31. [CrossRef] [Medline] [Web of Science]
18. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. [CrossRef] [Medline] [Web of Science]
19. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84. [Abstract/FREE Full text]
20. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11. [Medline] [Web of Science]
21. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. [CrossRef] [Medline] [Web of Science]
22. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30. [CrossRef] [Medline] [Web of Science]
23. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-24. [Abstract/FREE Full text]
24. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248. [Medline]
25. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147:583-6. [CrossRef] [Medline] [Web of Science]
26. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med 2008;25:860-2. [CrossRef] [Medline] [Web of Science]
27. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010;27:249-56. [CrossRef] [Medline] [Web of Science]
28. Scotland GS, McNamee P, Fleming AD, Goatman KA, Philip S, Prescott GJ, et al. Costs and consequences of automated algorithms versus manual grading for the detection of referable diabetic retinopathy. Br J Ophthalmol 2010;94:712-9. [Abstract/FREE Full text]
29. Browning DJ, Fraser CM, Clark S. The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology 2008;115:533-9. [CrossRef] [Medline] [Web of Science]
30. Scanlon PH. Why do patients still require surgery for the late complications of proliferative diabetic retinopathy? Eye (Lond) 2010;24:435-40. [Medline]
31. Hartnett ME, Key IJ, Loyacano NM, Horswell RL, Desalvo KB. Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol 2005;123:387-91. [Abstract/FREE Full text]
32. Lewis K, Patel D, Yorston D, Charteris D. A qualitative study in the United Kingdom of factors influencing attendance by patients with diabetes at ophthalmic outpatient clinics. Ophthalmic Epidemiol 2007;14:375-80. [CrossRef] [Medline] [Web of Science]
33. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001;79:435-40. [CrossRef] [Medline] [Web of Science]
34. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987;94:761-74. [Medline] [Web of Science]
35. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693-8. [CrossRef] [Medline] [Web of Science]
36. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-9, 1449. [CrossRef] [Medline] [Web of Science]
37. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7. [CrossRef] [Medline] [Web of Science]
38. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77. [CrossRef] [Medline] [Web of Science]
39. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50. [CrossRef] [Medline] [Web of Science]
40. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:365-8. [Abstract/FREE Full text]
41. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009;116:1943-8. [CrossRef] [Medline] [Web of Science]
42. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye (Lond) 2008;22:1337-41. [Medline]